A prospective, multicenter, observational study, which included 250 adult patients who underwent an alloHCT and subsequently received treatment for cGVHD, demonstrated that1
of patients with cGVHD require additional treatment following initial therapies.2
The clinically significant reductions in QOL that can occur with all severity grades (mild through severe) of cGVHD may be underestimated by physicians.3
QOL scores across all domains are lower in patients with greater cGVHD severity.3
aIn a national cross-sectional questionnaire study conducted in Japan, VAS scores were evaluated using 1140 pairs of patient and physician questionnaires. The data were collected from recipients of alloHCT for hematologic disease between 1995 and 2009. The VAS was used to assess the physical, psychological and social QOL of long-term survivors of alloHCT (median time post alloHCT of 7 years) who had various degrees of cGVHD severity.3
REZUROCK is an
evaluated in a real-world demographic of patients with cGVHD.5Explore the
alloHCT, allogeneic hematopoietic cell transplant; cGVHD, chronic graft-versus-host disease; GI, gastrointestinal; HLA, human leukocyte antigen; IST, immunosuppressive therapy; MDS, myelodysplastic syndrome; MOA, mechanism of action; QOL, quality of life; VAS, visual analog scale.
References: 1. Lee SJ, Nguyen TD, Onstad L, et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24(3):555-562. doi:10.1016/j.bbmt.2017.10.042 2. Bachier CR, Aggarwal SK, Hennegan K, Milgroom A, Rotto M. Epidemiology and real-world treatment of chronic graft-versus-host disease post allogeneic hematopoietic cell transplantation: a US claims analysis. Abstract presented at: The 62nd American Society of Hematology Conference. December 7, 2019; Orlando, FL. 3. Kurosawa S, Oshima K, Yamaguchi T, et al. Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(10):1749-1758. doi:10.1016/j.bbmt.2017.06.011 4. Hamilton BK, Storer BE, Wood WA, et al. Disability related to chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(4):772-777. doi:10.1016/j.bbmt.2019.10.019 5. REZUROCK. Package insert. Kadmon Pharmaceuticals, LLC; 2021.